ArticleScientific reports2026
Neuroprotective effect of intraperitoneal Humanin-G in retinal degeneration of Royal College of Surgeons rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
- Update of
Authors and funding
5 authors.
Funding
Abstract
This study aimed to examine whether Humanin-G (HNG), a mitochondrial derived peptide with cytoprotective properties, could improve the retinal function and gene expression in Royal College of Surgeons (RCS) rats with retinal pigment epithelium (RPE) dysfunction and retinal degeneration. Starting at postnatal day 21, RCS rats received twice a week intraperitoneal injection of either Low Dose HNG (0.4 mg/kg), High Dose HNG (4 mg/kg), or sham-saline for 1 or 4 weeks. Visual function was tested with electroretinography (ERG) and optokinetic testing (OKT). Then the rats were euthanized for RNA, cDNA and Quantitative Real-time PCR (qRT-PCR) analysis. The results showed that high dose HNG at 4 weeks after first injection (WAFI) was associated with the largest change in gene expression in the RPE and retina of treated animals, altering expression of genes involved in apoptosis, oxidative stress, inflammation and retinal/RPE function. At 4 WAFI, ERG showed no difference between either low or high dose of HNG and sham injection, while the visual acuity tested by OKT in rats treated with high dose HNG showed significant improvement. Our findings suggested that HNG can modulate gene expression and improve vision. Further studies are warranted to show whether HNG may be a potential treatment for retinal degeneration diseases.
Indexed as
Identifiers
42471450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.